Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jupiter: Deferasirox FCT vs DT Preference in Thalassemia
NCT02993224Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of deferasirox in thalassemia, sponsored by Novartis. Started Jul 2017; status: completed.
02
Drugs
deferasirox
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT02993224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993224.